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TRPV1 is a sensory transduction channel that mediates thermal nociception and some aspects of patholog-
ical pain. In this issue of Neuron, Gibson et al. report that TRPV1 also plays important roles in hippocampal
synaptic plasticity, presenting a potential challenge for TRPV1-targeted therapeutics for the treatment of
pain.Transient receptor potential vanilloid
1 (TRPV1) is a nonselective cation channel
activated by noxious heat, protons, sev-
eral endogenous lipid-derived signaling
molecules, and capsaicin, the pungent
compound from chili peppers (Levine
and Alessandri-Haber, 2007). TRPV1 is
present on peripheral sensory nerve end-
ings where it is thought to be a molecular
sensor of noxious heat. Although TRPV1
is normally activated at temperatures
much higher than body temperature, its
activation threshold shifts downward dur-
ing inflammation. This sensitization of the
channel underlies inflammation-induced
hypersensitivity to warm temperatures
that are normally innocuous, a phenome-
non that anyone with a sunburn trying to
take a warm shower can surely appreci-
ate. Recent evidence indicates that
TRPV1 is also expressed in the central
nervous system (CNS), although its func-
tion in different brain regions is not entirely
clear (Steenland et al., 2006). In this issue
of Neuron, Gibson and colleagues report
that TRPV1 is also a key mediator of
synaptic plasticity in the hippocampus
(Gibson et al., 2008), raising intriguing
questions about hippocampal function
and challenging the feasibility of targeting
TRPV1 for the treatment of pain.
One of the most studied forms of
synaptic plasticity is the use-dependent
potentiation of excitatory synapses onto
the pyramidal cells in area CA1 of the hip-
pocampus (Kullmann and Lamsa, 2007).
This long-term potentiation (LTP) is ro-
bustly produced by high-frequency stim-
ulation (HFS) of afferents in stratum radia-
tum (s. radiatum). While HFS produces
LTP in pyramidal cells, it simultaneouslydecreases the strength of excitatory syn-
apses from the same afferents onto inhib-
itory interneurons foundwithin s. radiatum
(McMahon and Kauer, 1997). Gibson and
colleagues sought to elucidate the mech-
anisms underlying this form of interneuron
long-term depression (iLTD). NMDA re-
ceptors (NMDAR) are molecular coinci-
dence detectors that underlie many forms
of synaptic plasticity. Interestingly, the
NMDAR antagonist D-AP5 had no effect
on iLTD. Moreover, NMDAR-mediated
EPSCs also showed LTD, suggesting
that iLTD is mediated by reduced gluta-
mate release from the presynaptic termi-
nal. This conclusion is supported by addi-
tional observations that HFS increased
the paired-pulse ratio, increased the fail-
ure rate of evoked EPSCs, and altered
the coefficient of variation of EPSC ampli-
tude.
Allof theseresultspoint towardapresyn-
aptic mechanism for iLTD, begging the
question, which receptors initiate which
retrograde messengers to signal presyn-
aptic changes? Application of an mGlu1
antagonist completely abolished iLTD.
mGlu1 is coupled to endocannabinoid sig-
naling in other systems, so it was a likely
possibility that postsynapticmGlu1activa-
tion would result in endocannabinoid
release across the synapse and activation
of presynaptic CB1 receptors. One CB1
receptor antagonist, SR141716A, elimi-
nated iLTD, while AM251, another CB1
antagonist, had no effect. This surprising,
if not troubling, result prompted further
investigation. Gibson and colleagues per-
formed an occlusion experiment to see
whether activation of CB1 receptor would
prevent HFS-induced iLTD. The CB1 re-Neuronceptor agonist, WIN55,212-2, did not
prevent HFS-induced iLTD, indicating
that CB1 receptors are probably not
involved in iLTD. This presented a puzzling
situation in which pharmacological agents
that are purported to have the same target
gave disparate results. In these situations,
onemight question the selectivity of one or
both of the drugs under consideration.
Indeed, a recent report indicated that
SR141716A may also antagonize TRPV1
(De Petrocellis et al., 2001), prompting
Gibson and colleagues to revise their
hypothesis to include TRPV1 as a potential
signaling component. Using an elegant
combination of pharmacology and genet-
ics, the authors show that TRPV1 is neces-
sary and sufficient for iLTD. They also pro-
vide evidence supporting amodel in which
an endogenous ligand of TRPV1, 12-(S)-
HPETE, is synthesized postsynaptically
and then acts on presynaptic TRPV1 to
produce iLTD.
In one experiment, Gibson and col-
leagues addressed the possible role of
TRPV1 in pyramidal cell synapses. They
found that neither capsaicin nor 12-(S)-
HPETE affect the synaptic strength of
CA3-CA1 pyramidal cell synapses. This
experiment and the iLTD experiments
demonstrate that excitatory synapses
onto pyramidal cells are functionally very
different than excitatory synapses onto
interneurons, despite the fact that they
arise from the same set of afferents. Inter-
estingly, a previous study found that cap-
saicin decreased evoked EPSCs in CA1
pyramidal neurons (Hajos and Freund,
2002), which seems to contradict the find-
ings of Gibson and colleagues. However,
Hajos and Freund used a 10-fold higher57, March 13, 2008 ª2008 Elsevier Inc. 629
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tained their slice preparation at a higher
temperature during their recordings.
Both alterations would significantly in-
crease TRPV1 activation compared to
the experimental conditions used by Gib-
son and colleagues. Taken together, it ap-
pears that oneof the functional differences
between the synapses onto CA1 pyrami-
dal cells and the synapses onto CA1 inter-
neurons is the relative sensitivity of the two
synapses to TRPV1 activation. At 10 mM
capsaicin, CA1 pyramidal cell evoked
EPSC amplitude is decreased (Hajos and
Freund, 2002). Gibson and colleagues
report that there are no changes in EPSC
amplitude following 1 mM capsaicin. Nev-
ertheless, Gibson and colleagues report
that this concentration of capsaicin elicits
TRPV1-mediated currents in CA1 and
CA3 pyramidal cells under their recording
conditions. This is consistent with several
other studies reporting the expression of
TRPV1 mRNA and protein in pyramidal
cells (Cristino et al., 2006; Mezey et al.,
2000; Toth et al., 2005). Interestingly,with-
out any TRPV1 activation, as in TRPV1/
mice, HFS-induced LTP is reduced
(Marsch et al., 2007). This last piece of
evidence argues for a model in which
TRPV1 is actively modulating synaptic
strength in two opposing directions—per-
haps decreasing presynaptic glutamate
release while increasing available AMPA
receptors postsynaptically. Strong activa-
tion of TRPV1may activate both potentiat-
ing and depressing mechanisms, but
synaptic depression is more robust or is
somehow upstream of the accompanying
potentiating mechanism. Weaker TRPV1
activation may only engage the potenti-
ating mechanisms, since TRPV1/ mice
have reduced LTP. Regardless, further
study will be required to clarify the role of
TRPV1 in excitatory synapses onto pyra-
midal cells. It is certainly possible that
TRPV1 does not play a role at pyramidal
cell synapses. If this is the case and if the
only function of TRPV1 in hippocampus
is to modulate iLTD, future studies could
utilize TRPV1 agonists and antagonists
to determine the behavioral relevance of
iLTD and the function of s. radiatum inter-
neurons.
This study by Gibson and colleagues
extends previous findings by the same
group concerning iLTD. Prior work
showed that this form of plasticity is not630 Neuron 57, March 13, 2008 ª2008 Elsevsynapse specific, since HFS of one set
of afferents induced synaptic depression
in a second independent set of afferents
that did not receive HFS (McMahon and
Kauer, 1997). In the current study, Gibson
and colleagues provide evidence for
a presynaptic locus of iLTD. Since iLTD
is presynaptically mediated but not syn-
apse specific, it is possible that 12-(S)-
HPETE diffuses from stimulated synapses
to unstimulated synapses on the same in-
terneuron where it could activate TRPV1
and reduce the strength of those synap-
ses. It is also possible that other signaling
molecules within interneurons, such as
Ca2+ or activated kinases, diffuse inside
the dendrite to unstimulated synapses
where they initiate the synthesis of
12-(S)-HPETE. This second model would
require less 12-(S)-HPETE production
overall, allowing for specific control of
interneuron synapses without ‘‘spillover’’
effects onto neighboring cells’ synapses.
Either way, iLTD represents a biological
balancing act that requires widespread
broadcasting of signals to unstimulated
synapses while maintaining some degree
of cellular specificity. Future studies into
the mechanisms behind this balancing
act will add to our knowledge of the
computational functions performed by
hippocampal circuits.
The results from this study have impor-
tant implications for the development of
drugs targeting TRPV1. There is an im-
mense body of work implicating TRPV1
in acute nociception, a normal physiolog-
ical process, as well as in pathological
pain states, including neuropathic and
inflammatory pain (Levine and Alessan-
dri-Haber, 2007). As such, there are sev-
eral TRPV1 antagonists in various stages
of drug development for the treatment of
pain (Szallasi et al., 2007). Although
TRPV1 is most strongly expressed in sen-
sory neurons, it has become clear that it is
functionally expressed in many other tis-
sues throughout the body, including the
central nervous system (Steenland et al.,
2006; Szallasi et al., 2007). These obser-
vations, as well as the results fromGibson
and colleagues, cloud the prospects of
TRPV1-targeted analgesics. If TRPV1 is
important in hippocampal synaptic plas-
ticity, as this study suggests, then sys-
temic TRPV1 antagonists may interfere
with many processes thought to rely on
hippocampal synaptic plasticity, such asier Inc.learning and memory. Indeed, TRPV1/
mice, which lack TRPV1 in all tissues,
have reduced anxiety and diminished
fear conditioning (Marsch et al., 2007).
Therefore, drugs targeting TRPV1 may
adversely affect cognitive function, repre-
senting a potential roadblock to the usage
of TRPV1 antagonists to treat pain.
However, there is a silver lining to this
cloud. The expression pattern of TRPV1
in the CNS includes expression in struc-
tures shown to be involved in pain pro-
cessing, such as the periaqueductal gray
(Steenland et al., 2006). Targeting these
receptors with TRPV1 antagonists that
act both centrally and peripherally actu-
ally produced greater analgesia than an-
tagonists thought to primarily act in the
periphery (Cui et al., 2006). A systemically
acting TRPV1 antagonist would therefore
act at multiple anatomic loci at the same
time to achieve analgesia. Moreover, if
TRPV1 antagonists cause adverse side
effects by interfering with CNS function,
other agents with lower CNS penetration
could still be systemically administered.
Of course, these antagonists could also
be locally applied. In other systems within
the CNS, TRPV1 receptor expressionmay
provide the opportunity for additional
uses of TRPV1-targeted drugs. For exam-
ple, TRPV1-mediated iLTD may contrib-
ute to epileptogenesis (see Discussion of
Gibson and colleagues). Regardless of
the uncertain future of TRPV1-targeted
therapeutics, studies like that of Gibson
and colleagues are important not only
for drug development but also for ex-
panding our knowledge of synaptic
function.
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By distinguishing groups of dopamin
Lammel and colleagues report in t
ventral tegmental area (VTA) form a
Dysregulation of dopamine systems un-
derlies a variety of disorders, ranging from
Parkinson’s disease to drug addiction. Un-
derstanding the physiology of these dopa-
mine neural networks is a key first step in
determining the etiology of these diseases.
In the midbrain, dopaminergic neurons are
broadly classified anatomically into the
Substantia Nigra pars compacta (SNc)
(A9) and the ventral tegmental area (VTA)
(A10). Projections from different dopamine
cells innervate the striatum, cortical re-
gions such as the prefrontal cortex, and
limbic structures such as the nucleus
accumbens (NAc) and amygdala. In very
broad terms, cells of the VTA innervate
mesocorticolimbic structures and cells of
the SNc innervate the dorsal striatum.
This is an oversimplification since substan-
tial anatomical overlap of thesenetworks is
known to exist (Bjorklund and Dunnett,
2007; Ikemoto, 2007).
To identify dopamine cells that form
specific networks, it is important (1) to
be able to relate the targets of individual
dopamine cells to specific behaviors
(Ikemoto, 2007), and (2) to catalog the
properties of the individual groups of
dopamine cells that project to those tar-
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intrinsic and pharmacological properties
to dopamine cells according to the targets
they innervate (Ford et al., 2006; Liss et al.,
2005; Margolis et al., 2006). However, to
date these studies have not provided an
overall explanation of how the intrinsic
properties of dopamine cells may mediate
differences in firing patters of individual
cells and the release of dopamine in
various projection areas (Garris and
Wightman, 1994).
In this issue of Neuron, Lammel et al.
(2008)make an important step by examin-
ing how the properties of individual dopa-
mine cells relate to the neural networks
they reside within. By making use of retro-
grade tracers, they identify specificgroups
of projecting dopamine neurons. Through
an exhaustive study, combining anato-
mical, electrophysiological, immunohisto-
chemical, and laser-dissected individual
mRNA-expression profiling based exami-
nations, they identify two populations of
mesocorticolimbic dopamine cells that
segregate according to their projection
targets.
The cell bodies of dopamine neurons
that project to themedial prefrontal cortex
(mPFC), medial accumbens shell, accum-
bens core, or amygdala originate in the
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n patterns and intrinsic properties,
olimbic dopamine neurons of the
medial posterior portion of the VTA. Do-
pamine cells that projected to the lateral
shell of the NAc were only observed in
more lateral portions of the VTA, partially
overlapping with SNc cells that project
to the dorsal striatum. These two groups
of dopamine cells (mPFC, accumbens
medial shell, and core and amygdala-pro-
jecting cells versus lateral shell and stria-
tal-projecting cells) also varied in their ex-
pression levels of mRNA for key markers
of dopamine cells. Markers included
mRNA for tyrosine hydroxylase (TH), do-
pamine transporter (DAT), and vesicular
monoamine transporter 2 (VMAT2). The
abundance of these markers covaried in
the two groups of neurons, being lower
in the group of neurons located in the
medial aspect of the VTA and higher in
neurons that projected to the lateral as-
pect of the NAc shell and dorsal striatum.
Thus, two broad groups of dopamine cells
were defined based on both anatomical
and biochemical characteristics.
The two groups of dopamine cells were
further distinguishedbasedon the intrinsic
electrophysiological properties. Classical
electrical properties of dopamine neurons
in brain slice preparations include slow
pacemaker firing, the presence of HCN
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